NEW DELHI (AP) – India said on Tuesday it would approve the use of all coronavirus vaccines that have been called to the emergency room by the World Health Organization or the United States, Europe, Britain or Japan.
The Indian Ministry of Health has said the decision is aimed at speeding up the use of staff in other countries and expanding the “vaccine basket” available for home use. The country of nearly 1.4 billion sees a pervasive wave of infections threatening hospital overcrowded cities.
According to experts, the only way out of the time of experts is to vaccinate more people.
But this has global implications, as India is a major producer of vaccines. Ներքին India’s domestic needs have delayed the delivery of staff to the UN-backed COVAX initiative, which aims to distribute fair vaccines.
Earlier, India launched the AstraZeneca vaccine developed by the Indian Serum Institute and the Bharat Biotech vaccine.
Vaccines that have been authorized for emergency use by the United States, Europe, Britain, Japan, or the World Health Organization can now be used in India. The Ministry of Health announced on Tuesday that the Russian Sputnik V vaccine had been given the green light for emergency use.
The Ministry of Health said that safety will be monitored by the first 100 people who will receive the footage before its use is expanded to include others.
Dr Shahid Amee Amil, a virus researcher at Ashoka University in India, said the move was unlikely to help the country overcome the current wave of vaccines, and that the release of the vaccines had been exported.
He said this would pave the way for India to use vaccines made by companies with manufacturing partners in India. For example, vaccine manufacturer Biological E Ltd was contracted to make the Johnson & Johnson coronavirus vaccine.
Ame Amil added that this is possible in addition to the vaccine market, which requires the sale of supercooling warehouses in cities where such facilities are located. Vaccine prices in India are currently set at Rs 250 or $ 3.30. This will help the government subsidize poor vaccines, while those who can afford to buy more expensive vaccines can do so.
Russia has contracts with five Indian pharmaceutical companies to make more than 850 million doses of Sputnik V vaccine for the world in India. It has entered into a deal with Dr Reddy’s Laboratories to conduct late trials in India to distribute up to 250 million shares.
But under the terms of four of Russia’s five deals in March-April, the doses are likely to be delivered during the year. Moreover, Russia’s first deal with India was for Hetero Biopharma for 100 million doses, but it is unclear whether it has started dosing. Hetero Biopharma did not respond to a request from The Associated Press.
The Associated Press Health Science Department is supported by the Science Education Department of Howard Hughes Medical Institute. The AP is solely responsible for all content.